1056 related articles for article (PubMed ID: 17879211)
21. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
22. Elevated matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in obese children and adolescents.
Głowińska-Olszewska B; Urban M
Metabolism; 2007 Jun; 56(6):799-805. PubMed ID: 17512313
[TBL] [Abstract][Full Text] [Related]
23. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
24. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
25. [Serum and urinary concentration of selected metalloproteinases and their tissue inhibitors in children with vesicoureteral reflux].
Taranta-Janusz K; Zoch-Zwierz W; Wasilewska A; Tenderenda E; Korzeniecka-Kozerska A
Pol Merkur Lekarski; 2010 Aug; 29(170):88-92. PubMed ID: 20842819
[TBL] [Abstract][Full Text] [Related]
26. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
27. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents.
Belo VA; Souza-Costa DC; Lana CM; Caputo FL; Marcaccini AM; Gerlach RF; Bastos MG; Tanus-Santos JE
Clin Biochem; 2009 Jul; 42(10-11):984-90. PubMed ID: 19358835
[TBL] [Abstract][Full Text] [Related]
28. [Serum levels of matrix metaloproteinase 2 (MMP-2), matrix metaloproteinase 9 (MMP-9) and tissue inhibitor of metaloproteinase 2 (TIMP-2) in children and adolescents with growth hormone deficiency].
Szczepańska-Kostro J; Kowalewski M; Urban M; Gardziejczyk M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(4):257-60. PubMed ID: 17239302
[TBL] [Abstract][Full Text] [Related]
29. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
30. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
31. Effect of angiotensin II receptor blocker on glucose-induced mRNA expressions of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in rat mesangial cells.
Ding HL; Guo Y; Xu MT; Li HY; Fu ZZ
Chin Med J (Engl); 2007 Nov; 120(21):1886-9. PubMed ID: 18067760
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
[TBL] [Abstract][Full Text] [Related]
34. Occurrence of matrix metalloproteinases and tissue inhibitors of metalloproteinases in tuberculous pleuritis.
Hoheisel G; Sack U; Hui DS; Huse K; Chan KS; Chan KK; Hartwig K; Schuster E; Scholz GH; Schauer J
Tuberculosis (Edinb); 2001; 81(3):203-9. PubMed ID: 11466032
[TBL] [Abstract][Full Text] [Related]
35. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
[TBL] [Abstract][Full Text] [Related]
36. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension.
Tan J; Hua Q; Xing X; Wen J; Liu R; Yang Z
Hypertens Res; 2007 Oct; 30(10):959-63. PubMed ID: 18049028
[TBL] [Abstract][Full Text] [Related]
37. Different circulating metalloproteinases profiles in women with migraine with and without aura.
Martins-Oliveira A; Speciali JG; Dach F; Marcaccini AM; Gonçalves FM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 Oct; 408(1-2):60-4. PubMed ID: 19627981
[TBL] [Abstract][Full Text] [Related]
38. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
39. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
[TBL] [Abstract][Full Text] [Related]
40. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]